Clinical trial
The Effects of Tildrakizumab in Treatment of Bullous Pemphigoid
NCT04465292 is registered in ClinicalTrials.gov with Brigham and Women's Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- The Effects of Tildrakizumab in Treatment of Bullous Pemphigoid
- Lead sponsor
- Brigham and Women's Hospital
- Phase
- Phase 1
- Overall status
- Unknown status
- Start date
- September 1, 2020
- Completion date
- May 1, 2023
- Enrollment
- 16 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.